Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 101Leukemia 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 95Myelodysplastic Syndromes 83Leukemia, Lymphocytic, Chronic, B-Cell 78Lymphoma, Non-Hodgkin 76Multiple Myeloma 67Hodgkin Disease 67Lymphoma, Mantle-Cell 63Lymphoma 62Lymphoma, Large B-Cell, Diffuse 60Lymphoma, Follicular 59Leukemia, Myeloid, Chronic-Phase 57Lymphoma, B-Cell, Marginal Zone 53Burkitt Lymphoma 53Lymphoma, Large-Cell, Immunoblastic 49Leukemia, Myeloid, Accelerated Phase 48Congenital Abnormalities 48Myeloproliferative Disorders 46Leukemia, Myelomonocytic, Chronic 43Anemia, Refractory, with Excess of Blasts 41Graft vs Host Disease 37Leukemia, Myelogenous, Chronic, BCR-ABL Positive 36Blast Crisis 33Recurrence 32Dendritic Cell Sarcoma, Interdigitating 32Primary Myelofibrosis 27Lymphoma, T-Cell, Cutaneous 27Neoplasms, Plasma Cell 26Waldenstrom Macroglobulinemia 25

Interventions

Cytarabine 14fludarabine 13venetoclax 11Imatinib Mesylate 9Cyclophosphamide 8Azacitidine 8fludarabine phosphate 7Busulfan 7Whole-Body Irradiation 6Tacrolimus 6Mycophenolic Acid 6thymoglobulin 4ponatinib 4nilotinib 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4asciminib 3aldesleukin 3Melphalan 3Interleukin-2 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Decitabine 3Bone Marrow Transplantation 3Antilymphocyte Serum 3zosuquidar trihydrochloride 2gilteritinib 2enasidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid × Cyclosporine × Clear all
NCT00568633 2019-09-24

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Stanford University

Phase 3 Terminated
58 enrolled 18 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT01392989 2019-05-07

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Stanford University

Phase 2 Completed
44 enrolled 13 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neural Tube Defects

Data powered by HemOnc (CC BY 4.0) Colophon âš¡